

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI868549

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name			Execution Date
Cambrex Charles City, Inc.			03/06/2025
RECEIVING PARTY DATA			
Company Name:	Ares Agent Services, L.P., as Collateral Agent		
Street Address:	245 Park Avenue		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10167		
PROPERTY NUMBERS Total: 3			
Property Type	Number		
Application Number:	13378176		
Application Number:	12466457		
Application Number:	16755719		
CORRESPONDENCE DATA			
Fax Number:	2127514864		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2129061209		
Email:	jess.bajada-bartlett@lw.com		
Correspondent Name:	Mrs. Jessica Bajada-Bartlett		
Address Line 1:	1271 Avenue of the Americas		
Address Line 4:	New York, NEW YORK 10020		
ATTORNEY DOCKET NUMBER:	042742-0274		
NAME OF SUBMITTER:	Jessica Bajada-Bartlett		
SIGNATURE:	/Jessica Bajada-Bartlett/		
DATE SIGNED:	03/06/2025		
Total Attachments: 7			
source=Cambrex - Patent Security Agreement [Executed - 3.6.25](157815590.1)#page1.tiff			
source=Cambrex - Patent Security Agreement [Executed - 3.6.25](157815590.1)#page2.tiff			
source=Cambrex - Patent Security Agreement [Executed - 3.6.25](157815590.1)#page3.tiff			
source=Cambrex - Patent Security Agreement [Executed - 3.6.25](157815590.1)#page4.tiff			

source=Cambrex - Patent Security Agreement [Executed - 3.6.25](157815590.1)#page5.tiff

source=Cambrex - Patent Security Agreement [Executed - 3.6.25](157815590.1)#page6.tiff

source=Cambrex - Patent Security Agreement [Executed - 3.6.25](157815590.1)#page7.tiff

PATENT

REEL: 070421 FRAME: 0948

PATENT SECURITY AGREEMENT

This Patent Security Agreement (this “Agreement”), dated as of March 6, 2025, is entered into by Cambrex Charles City, Inc., an Iowa corporation, Avista Pharma Solutions, Inc., a Delaware corporation, and Snapdragon Chemistry, Inc., a Delaware corporation (each, a “Grantor”, and collectively, the “Grantors”) in favor of Ares Agent Services, L.P., as collateral agent (together with its successors and assigns, in such capacity, the “Collateral Agent”).

WHEREAS, the Grantors and certain other parties have executed and delivered that certain Pledge and Security Agreement, dated on even date herewith, in favor of the Collateral Agent (the “Pledge and Security Agreement”) pursuant to which the Grantors and certain other parties have granted to Collateral Agent, for the benefit of the Secured Parties, a security interest in all of the Grantors’ and certain other parties’ right, title, and interest in and to certain collateral including the Patent Collateral (as defined below);

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors and the Collateral Agent hereby agree as follows:

SECTION 1. Defined Terms. Capitalized terms not otherwise defined herein have the meanings set forth in the Pledge and Security Agreement.

SECTION 2. Grant of Security Interest. Subject to the terms of the Pledge and Security Agreement, each Grantor hereby pledges and grants to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all of such Grantor’s right, title and interest in, to and under the following, in each case whether now owned or existing or hereafter acquired, as collateral security for the prompt and complete payment and performance when due of the obligations of such Grantor: (i) all Patents owned by such Grantor, including, without limitation, the issued Patents and Patent applications set forth on Schedule A attached hereto, and all rights corresponding thereto throughout the world, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, and reexaminations of any of the foregoing; (iii) the right to sue for past, present and future infringements of any of the foregoing, and (iv) all proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit (collectively, the “Patent Collateral”).

SECTION 3. Security Agreement. The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the Secured Parties pursuant to the Pledge and Security Agreement, and each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Pledge and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Agreement is deemed to conflict with the Pledge and Security Agreement, the provisions of the Pledge and Security Agreement shall control.

SECTION 4. Termination or Release. Upon the termination of the Pledge and Security Agreement or the release of the Patent Collateral, in each case, in accordance with the terms of the Pledge and Security Agreement, the Collateral Agent shall execute, acknowledge and deliver to each Grantor an instrument in writing in recordable form releasing the collateral pledge, grant, lien and security interest in the Patent Collateral under this Agreement.

SECTION 5. Recordation. Each Grantor authorizes and requests that the Commissioner of Patents and Trademarks of the United States Patent and Trademark Office and any other applicable government officer to record this Agreement.


SECTION 6. Governing Law. This agreement and the rights and obligations of the parties hereunder and any claim or controversy relating hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York, without regard to its conflicts of laws principles.

SECTION 7. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. The words "execution," "execute," "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Signature pages follow]


IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

CAMBREX CHARLES CITY, INC.,
as a Grantor


By: 
Name: Robert Green
Title: Vice President and Treasurer

By: _____
Name: Samantha Hanley
Title: Vice President and Secretary

AVISTA PHARMA SOLUTIONS, INC.,
as a Grantor

By: 
Name: Robert Green
Title: Vice President and Treasurer

SNAPDRAGON CHEMISTRY, INC.,
as a Grantor

By: 
Name: Robert Green
Title: Vice President and Treasurer

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

CAMBREX CHARLES CITY, INC.,
as a Grantor

By: _____
Name: Robert Green
Title: Vice President and Treasurer

By: *Samantha Hanley*
Name: Samantha Hanley
Title: Vice President and Secretary

AVISTA PHARMA SOLUTIONS, INC.,
as a Grantor

By: _____
Name: Robert Green
Title: Vice President and Treasurer

SNAPDRAGON CHEMISTRY, INC.,
as a Grantor

By: _____
Name: Robert Green
Title: Vice President and Treasurer

Ares Agent Services, L.P., as Collateral Agent

By: 
Name: Mark Affolter
Title: Authorized Signatory

[Signature Page to Patent Security Agreement]

PATENT
REEL: 070421 FRAME: 0953

SCHEDULE A

PATENTS

<u>Title</u>	<u>Grantor</u>	<u>Application Number</u>	<u>Filing Date</u>	<u>Patent Number</u>	<u>Issue Date</u>
Automated online chromatographic sample dilution and preparation system	Snapdragon Chemistry, Inc.	17/340264	2021-06-07	11994502	2024-05-28
Continuous flow photoreactor	Snapdragon Chemistry, Inc.	16/986503	2020-08-06	11998887	2024-06-04
Methods and compositions for preparation of amphetamine conjugates and salts thereof	Cambrex Charles City, Inc.	13/378176	2010-06-18	8614346	2013-12-24
Method of making amphetamine	Cambrex Charles City, Inc.	12/466457	2009-05-15	7705184	2010-04-27
Methods of o-demethylation	Cambrex Charles City, Inc.	16/755719	2018-10-12	11136331	2021-10-05
Antiparasitic compounds	Avista Pharma Solutions, Inc.	15/849834	2017-12-21	10092001	2018-10-09
Antiparasitic compounds	Avista Pharma Solutions, Inc.	16/123251	2018-09-06	10342234	2019-07-09
Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazol[1,2- α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin ep4 receptor antagonist	Avista Pharma Solutions, Inc.	16/100315	2018-08-10	10239885	2019-03-26
Synthetic process and intermediates	Avista Pharma Solutions, Inc.	16/302944	2017-05-17	10556909	2020-02-11
Substituted ureas as prostaglandin ep4 receptor antagonists	Avista Pharma Solutions, Inc.	16/263518	2019-01-31	10570144	2020-02-25
Synthetic process and intermediates	Avista Pharma Solutions, Inc.	16/775451	2020-01-29	11512088	2022-11-29
Chemical compounds	Avista Pharma Solutions, Inc.	16/775596	2020-01-29	11459331	2022-10-04

PATENT

<u>Title</u>	<u>Grantor</u>	<u>Application Number</u>	<u>Filing Date</u>	<u>Patent Number</u>	<u>Issue Date</u>
Chemical compounds	Avista Pharma Solutions, Inc.	17/903216	2022-09-06		

PATENT

REEL: 070421 FRAME: 0955

RECORDED: 03/06/2025